Overview

A Study of SEA-CD40 Given With Other Drugs in Cancers

Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.
Phase:
Phase 2
Details
Lead Sponsor:
Seagen Inc.
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Carboplatin
Pembrolizumab
Pemetrexed